Advertisement

Konservative Therapie des chronischen Ulkusleidens — Medikamente für den Ulkusschub

  • W. Domschke
Conference paper
Part of the Interdisziplinäre Gastroenterologie book series (GASTROENTEROLOG)

Zusammenfassung

Die Therapie des Ulkusschubs hat im wesentlichen 3 Zielsetzungen:
  1. 1)

    Beschwerdefreiheit des Patienten,

     
  2. 2)

    Beschleunigung der Ulkusheilung und Verhinderung von Ulkus-komplikationen,

     
  3. 3)

    womöglich Prophylaxe des Ulkusrezidivs ohne Langzeittherapie.

     

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Blum AL, Hammer R (1979) Die Behandlung des Ulcus pepticum mit Pirenzepin. Demeter, GräfelfmgGoogle Scholar
  2. 2.
    Blum AL, Siewert JR, Halter F (1978) Ulkustherapie mit Cimetidin. Dtsch Med Wo-chenschr 103:135CrossRefGoogle Scholar
  3. 3.
    Cohen MM, Cheung G, Lyster DM (1980) Prevention of aspirin induced faecal blood loss by prostaglandin E2. Gut 21:602PubMedCrossRefGoogle Scholar
  4. 4.
    Dammann HG, Müller P, Simon B (1982) Inhibition of nocturnal acid secretion by H2-receptor antagonist SKF 93479. Lancet 1:224PubMedCrossRefGoogle Scholar
  5. 5.
    Domschke W, Domschke S, Hagel J, Demling L, Croft DN (1977) Gastric epithelial cell turnover, mucus production, and healing of gastric ulcers with carbenoxolone. Gut 18:817PubMedCrossRefGoogle Scholar
  6. 6.
    Domschke W, Lux G, Domschke S (1980) Furan H2-antagonist ranitidine inhibits pen-tagastrin-stimulated gastric secretion stronger than Cimetidine. Gastroenterology 79:1267PubMedGoogle Scholar
  7. 7.
    Eckardt VF, Kanzler G, Willems D et al. (1982) Therapie des Ulcus duodeni mit Cimetidin. Vergleichende Untersuchungen der Wirksamkeit von zwei Dosierungen. Dtsch Med Wochenschr 107:60PubMedCrossRefGoogle Scholar
  8. 8.
    Englert E, Freston JW, Graham DY et al. (1978) Cimetidine, antacid, and hospitalization in the treatment of benign gastric ulcer. Gastroenterology 74:416PubMedGoogle Scholar
  9. 9.
    Fedeli G, Anti M, Rapaccini GL, De Vitis I, Butti A, Civello IM (1979) A controlled study comparing Cimetidine treatment to an intensive antacid regimen in the therapy of uncomplicated duodenal ulcer. Dig Dis Sci 24:758PubMedCrossRefGoogle Scholar
  10. 10.
    Fortran JS, Morawski SG, Richardson CT (1973) In vivo and in vitro evaluation of liquid antacids. N Engl J Med 288:923CrossRefGoogle Scholar
  11. 11.
    Hung JN, Franz DR (1981) Effect of prostaglandin E2 on gastric mucosal bleeding caused by aspirin. Dig Dis Sci 26:301CrossRefGoogle Scholar
  12. 12.
    Ippoliti AF, Sturdevant RAL, Isenberg JI et al. (1978) Cimetidine versus intensive antacid therapy for duodenal ulcer. Gastroenterology 74:393PubMedGoogle Scholar
  13. 13.
    Johansson C, Kollberg B (1981) E2-Prostaglandine — potentielle Substanzen zur Behandlung des peptischen Ulkus. In: Holtermüller KH, Malagelada JR, Herzog P (Hrsg) Pathogenese und Therapie der Ulkuserkrankung. Excerpta Medica, Amsterdam, S 300Google Scholar
  14. 14.
    Johansson C, Kollberg B, Nordemar R, Samuelson K, Bergström S (1980) Protective effect of prostaglandin E2 in the gastrointestinal tract during indomethacin treatment of rheumatic diseases. Gastroenterology 78:479PubMedGoogle Scholar
  15. 15.
    Kayasseh L, Keller U, Gyr K (1980) Somatostatin and Cimetidine in peptic-ulcer haemorrhage. Lancet 1:844PubMedCrossRefGoogle Scholar
  16. 16.
    Kollberg B, Slezak P (im Druck) The effect of prostaglandin E2 on duodenal ulcer healing. Scand J GastroenterolGoogle Scholar
  17. 17.
    Lam SK, Lam KC, Lai CL, Yeung CK, Yam LYC, Wong WS (1979) Treatment of duodenal ulcer with antacid and sulpiride. Gastroenterology 76:315PubMedGoogle Scholar
  18. 18.
    Marks IN, Wright JP, Denyer M, Garish JAM, Lücke W (1980) Comparison of sucralfate with Cimetidine in the short-term treatment of chronic peptic ulcers. S Afr Med J 57:567PubMedGoogle Scholar
  19. 19.
    Marks IN, Lucke W, Wright JP, Girdwood AH (1981) Ulcer healing and relapse rates after initial treatment with Cimetidine or sucralfate. J Clin Gastroenterol [Suppl 2] 3:163PubMedGoogle Scholar
  20. 20.
    Martin DF, May SJ, Tweedle DEF, Hollanders D, Ravenscroft MM, Miller JP (1981) Difference in relapse rates of duodenal ulcer after healing with Cimetidine or tripotas-sium dicitrato bismuthate. Lancet 1:7PubMedCrossRefGoogle Scholar
  21. 21.
    Misiewicz JJ (1981) Medical treatment of peptic ulcer. In: Domschke W, Wormsley KG (Hrsg) Magen und Magenkrankheiten. Thieme, Stuttgart New York, S 262Google Scholar
  22. 22.
    Olbe L, Haglund U, Leth R et al. (1982) Effects of substituted benzimidazole (H 149/ 94) on gastric acid secretion in humans. Gastroenterology 83:193PubMedGoogle Scholar
  23. 23.
    Pace F, Domschke W, Eichenberger P et al. (1982) Gelusil und Tagamet bei der ambulanten Therapie des Ulcus ventriculi: Resultate der Gelumet-Studie. Z Gastroenterol 20:528Google Scholar
  24. 24.
    Peterson WL, Sturdevant RAL, Frankl HD et al. (1977) Healing of duodenal ulcer with an antacid regimen. N Engl J Med 297:341PubMedCrossRefGoogle Scholar
  25. 25.
    Ruppin H, Person B, Robert A, Domschke W (1981) Gastric cytoprotection in man by prostaglandin E2. Scand J Gastroenterol 16:647PubMedCrossRefGoogle Scholar
  26. 26.
    Vantrappen G, Popiela T, Tytgat DNJ, Lambert R, Robert A (1980) A multicenter trial of 15(R)-15-methyl prostaglandin E2 in duodenal ulcer. Gastroenterology 78:1283Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1984

Authors and Affiliations

  • W. Domschke

There are no affiliations available

Personalised recommendations